Order Article Reprints

de Braud F, Machiels J-PH, Boggiani D, Rottey SWH, Duca M, Laruelle M, Salvagni S, Damian S, Lapeire LDF, Tiseo M, et al. A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors. Cancers. 2020; 12(6):1425. https://doi.org/10.3390/cancers12061425

de Braud, Filippo, Jean-Pascal H. Machiels, Daniela Boggiani, Sylvie W.H. Rottey, Matteo Duca, Marie Laruelle, Stefania Salvagni, Silvia Damian, Lore D.F. Lapeire, Marcello Tiseo, and et al. 2020. "A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors" Cancers 12, no. 6: 1425. https://doi.org/10.3390/cancers12061425

de Braud, F., Machiels, J.-P. H., Boggiani, D., Rottey, S. W. H., Duca, M., Laruelle, M., Salvagni, S., Damian, S., Lapeire, L. D. F., Tiseo, M., Dermine, A., Ould-Kaci, M., Braunger, J., Rascher, J., Fischer, D., Hoefler, J., Mariani, G. L., & Cresta, S. (2020). A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors. Cancers, 12(6), 1425. https://doi.org/10.3390/cancers12061425